Delivery Order SPE2DB22D3501-SPE2DB25FWS72
- Not listed
- The U.S. Defense Logistics Agency's Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp for $9,584.58 to supply Trodelvy 180 mg vials, with an ultimate completion date of August 26, 2025. This competitively awarded, firm fixed-price delivery order was issued on August 5, 2025, with no set-aside designation. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, serves as the prime contractor and will perform the work at its corporate office location in...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 24, 2025, for the supply of Trodelvy 180 mg vials with a ceiling value of $9,584.58. This firm fixed-price delivery order, with an ultimate completion date of August 14, 2025, represents a non-set-aside competitive award. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency awarded a $9,584.58 delivery order to AmerisourceBergen Drug Corp for the supply of Trodelvy 180 mg vials, with a completion date of August 15, 2025. This competitively awarded, firm fixed-price delivery order reflects the pharmaceutical distributor's ongoing role as a critical medical supplier to federal healthcare systems. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency's Medical Supply Chain awarded a $9,584.58 firm fixed-price delivery order to AmerisourceBergen Drug Corp on July 28, 2025, for the supply of Trodelvy 180 mg vials, with an ultimate completion date of August 18, 2025. This non-set-aside award represents a child delivery order issued under AmerisourceBergen's broader Indefinite Delivery Contract (IDC SPE2DX) with DLA Troop Support Medical, valued at $999,999,999 and extending through December 2026....
- AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, received a $9,584.58 firm fixed-price delivery order from the Defense Logistics Agency (DLA) on July 22, 2025, for the supply of Trodelvy 180 mg vials. The award is a child contract issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. This delivery order was competitively awarded without a set-aside...
- The Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order contract to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, to provide 180 mg vials of the specialty pharmaceutical drug Trodelvy. The contract has a ceiling value of $9,010.50 and a period of performance through April 1, 2024. This delivery order is issued under a larger indefinite delivery contract (IDC) between DLA and Amerisourcebergen Drug Corp with a potential value of $999,999,999.00...
- This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of Trodelvy 180 mg vials. The contract has a ceiling value of $6,389.72 and a performance period ending on May 22, 2025. It is a firm fixed-price contract, and there is no set-aside designation, indicating open competition. AmerisourceBergen Drug Corp holds a larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical,...
- The Defense Logistics Agency (DLA) awarded a firm fixed price delivery order contract worth $9,010.50 to Amerisourcebergen Drug Corp, the prime contractor, to provide 180 mg vials of the pharmaceutical drug TRODELVY. The contract has a completion date of March 7, 2024 and was awarded on February 14, 2024. This delivery order falls under a larger indefinite delivery contract (IDC) between DLA and Amerisourcebergen Drug Corp with a potential value of $999,999,999.00 and a performance period...
- The Defense Logistics Agency (DLA) awarded a firm fixed price delivery order contract valued at $18,021.00 to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, to provide the pharmaceutical product TRODELVY 180 MG VIALS. This delivery order is part of a larger indefinite delivery contract (IDC) awarded solely to Amerisourcebergen Drug Corp, with a potential value of $999,999,999.00 and a period of performance through December 31, 2025. The IDC serves as the primary...
- This is a delivery order awarded by the Defense Logistics Agency (DLA) Troop Support Medical to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $12,779.44 firm fixed-price contract is for the supply of TRODELVY 180 MG VIALS, a specialty medication. The contract has an ultimate completion date of March 4, 2025 and was awarded on February 10, 2025. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the...
- SPE2DB22D3501Indefinite Delivery Contract
- SPE2DB22D3501-SPE2DB25FWS72Delivery Order
The Defense Logistics Agency awarded a $6,389.72 firm fixed price delivery order to AmerisourceBergen Drug Corp for the supply of Trodelvy 180 mg vials, with an ultimate completion date of August 25, 2025. This non-set-aside competitive award represents a single delivery order issued under AmerisourceBergen's larger pharmaceutical supply contract vehicle. The product will be delivered to the company's corporate office location in Conshohocken, Pennsylvania. This delivery order is a child contract executed under AmerisourceBergen's Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999 and running through December 2026. That prime contract vehicle provides comprehensive global pharmaceutical support to military healthcare programs, enabling AmerisourceBergen to supply a broad range of medications, vaccines, and medical supplies across multiple therapeutic domains to the Defense Health Agency, U.S. Coast Guard, and other federal healthcare systems. Trodelvy, a specialty pharmaceutical product, falls within the scope of oncology and specialized medications supported through this arrangement.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $6.4k | 8/4/25 |